{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:49:09Z","timestamp":1791575349131,"version":"4.3.4"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"5","funder":[{"name":"Center for Cancer Research, National Cancer Institute, National Institutes of Health Intramural Research","award":["ZIA BC 010453"],"award-info":[{"award-number":["ZIA BC 010453"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer disproportionately affects vulnerable populations. The All of Us Research Program (AoURP) is a database that aims to encapsulate the diversity of the United States. To explore the utility of this dataset in assessing prostate cancer disparities, we investigated whether treatment usage, disease progression, and genomic research participation vary across sociodemographic factors among AoURP participants with prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified AoURP participants with prostate cancer. Genomic research participation in AoURP, treatment usage, time-to-treatment, and time-to-metastasis were assessed by demographics and distance from a National Cancer Institute\u2013designated comprehensive cancer center. Multivariable logistic regression and Cox proportional hazards regression were performed to evaluate treatment usage and time-to-treatment and time-to-metastasis, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed lower genomic data availability in Black vs White patients (P\u2009&amp;lt;\u2009.001). In multivariable analyses, patients residing more than 80 miles from an NCI-designated comprehensive cancer center were less likely to receive androgen receptor pathway inhibitors (odds ratio [OR]\u2009=\u20090.30, 95% CI = 0.14 to 0.66; P\u2009=\u2009.002) and bone targeting agents (OR\u2009=\u20090.46, 95% CI = 0.30 to 0.70; P\u2009&amp;lt;\u2009.001) but more likely to undergo prostatectomy (OR\u2009=\u20091.97, 95% CI = 1.43 to 2.71; P\u2009&amp;lt;\u2009.001) than those\u2009residing less than\u200940 miles away. These patients also initiated treatment faster (hazard ratio [HR]\u2009=\u20091.54, 95% CI = 1.27 to 1.87; P\u2009&amp;lt;\u2009.001) and developed metastasis slower (HR\u2009=\u20090.58, 95% CI = 0.40 to 0.86; P\u2009=\u2009.006). Black patients were less likely to receive radiation (OR\u2009=\u20090.45, 95% CI = 0.23 to 0.88; P\u2009=\u2009.020), prostatectomy (OR\u2009=\u20090.65, 95% CI = 0.44 to 0.96; P\u2009=\u2009.028), and bone targeting agents (OR\u2009=\u20090.65, 95% CI = 0.45 to 0.93; P\u2009=\u2009.018) than White patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prostate cancer treatment usage, disease progression, and genomic research participation varied between demographic populations. As AoURP matures, additional studies may leverage future data releases to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jncics\/pkag070","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:36:19Z","timestamp":1782876979000},"source":"Crossref","is-referenced-by-count":0,"title":["Sociodemographic trends in prostate cancer: insights from the All of Us Research Program"],"prefix":"10.1093","volume":"10","author":[{"given":"Dhruv G","family":"Pillai","sequence":"first","affiliation":[{"name":"Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8478-2465","authenticated-orcid":false,"given":"Vivian A","family":"Guedes","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G","family":"Micheletti","sequence":"additional","affiliation":[{"name":"Office of Collaborative Biostatistics, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica D","family":"Kindrick","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6713-3292","authenticated-orcid":false,"given":"Benjamin C","family":"Brim","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8756-1016","authenticated-orcid":false,"given":"Hyoyoung","family":"Choo-Wosoba","sequence":"additional","affiliation":[{"name":"Office of Collaborative Biostatistics, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-3833","authenticated-orcid":false,"given":"Cindy H","family":"Chau","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2428-5613","authenticated-orcid":false,"given":"William D","family":"Figg","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD,","place":["United States"]},{"name":"Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"2026100914520038100_pkag070-B1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3322\/caac.70028","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026100914520038100_pkag070-B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.canlet.2022.01.028","article-title":"Racial disparities in prostate cancer: a complex interplay between socioeconomic inequities and genomics","volume":"531","author":"Lowder","year":"2022","journal-title":"Cancer Lett"},{"key":"2026100914520038100_pkag070-B3","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1002\/cncr.34433","article-title":"Racial disparities in Black men with prostate cancer: a literature review","volume":"128","author":"Lillard","year":"2022","journal-title":"Cancer"},{"key":"2026100914520038100_pkag070-B4","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jamcollsurg.2015.01.056","article-title":"Impact of National Cancer Institute comprehensive cancer centers on ovarian cancer treatment and survival","volume":"220","author":"Bristow","year":"2015","journal-title":"J Am Coll Surg"},{"key":"2026100914520038100_pkag070-B5","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1002\/cncr.29576","article-title":"Impact of care at comprehensive cancer centers on outcome: results from a population-based study","volume":"121","author":"Wolfson","year":"2015","journal-title":"Cancer"},{"key":"2026100914520038100_pkag070-B6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ygyno.2016.10.004","article-title":"Distance from a comprehensive cancer center: a proxy for poor cervical cancer outcomes?","volume":"143","author":"Barrington","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2026100914520038100_pkag070-B7","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/cncr.32666","article-title":"Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system","volume":"126","author":"Riviere","year":"2020","journal-title":"Cancer"},{"key":"2026100914520038100_pkag070-B8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41391-018-0083-4","article-title":"Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer","volume":"22","author":"Krimphove","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026100914520038100_pkag070-B9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.prnil.2019.08.001","article-title":"A review of social determinants of prostate cancer risk, stage, and survival","volume":"8","author":"Coughlin","year":"2020","journal-title":"Prostate Int"},{"key":"2026100914520038100_pkag070-B10","doi-asserted-by":"publisher","first-page":"91.e1","DOI":"10.1016\/j.urolonc.2017.10.023","article-title":"The effect of socioeconomic status, race, and insurance type on newly diagnosed metastatic prostate cancer in the United States (2004-2013)","volume":"36","author":"Weiner","year":"2018","journal-title":"Urol Oncol"},{"key":"2026100914520038100_pkag070-B11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.juro.2011.10.156","article-title":"Impact of distance to a urologist on early diagnosis of prostate cancer among Black and White patients","volume":"187","author":"Holmes","year":"2012","journal-title":"J Urol"},{"key":"2026100914520038100_pkag070-B12","author":"National Cancer Institute"},{"key":"2026100914520038100_pkag070-B13","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1093\/tbm\/ibab091","article-title":"Financial toxicity in cancer care: origins, impact, and solutions","volume":"11","author":"Abrams","year":"2021","journal-title":"Transl Behav Med"},{"key":"2026100914520038100_pkag070-B14","doi-asserted-by":"publisher","first-page":"e0259815","DOI":"10.1371\/journal.pone.0259815","article-title":"The role of health literacy in cancer care: a mixed studies systematic review","volume":"16","author":"Holden","year":"2021","journal-title":"PLoS One"},{"key":"2026100914520038100_pkag070-B15","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/jnci\/djaf355","article-title":"Social vulnerability and clinical trial enrollment: the next frontier of health equity","volume":"118","author":"Perati","year":"2026","journal-title":"J Natl Cancer Inst"},{"key":"2026100914520038100_pkag070-B16","doi-asserted-by":"publisher","first-page":"865786","DOI":"10.3389\/fpubh.2023.865786","article-title":"Factors that influence a patient\u2019s decision to engage in genetic research","volume":"11","author":"Almutairi","year":"2023","journal-title":"Front Public Health"},{"key":"2026100914520038100_pkag070-B17","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1377\/hlthaff.2017.1595","article-title":"Lack of diversity in genomic databases is a barrier to translating precision medicine research into practice","volume":"37","author":"Landry","year":"2018","journal-title":"Health Aff (Millwood)"},{"key":"2026100914520038100_pkag070-B18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41591-023-02744-3","article-title":"The All of Us Research Program is an opportunity to enhance the diversity of US biomedical research","volume":"30","author":"Bianchi","year":"2024","journal-title":"Nat Med"},{"key":"2026100914520038100_pkag070-B19","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1056\/NEJMsr1809937","article-title":"The \u201cAll of Us\u201d research program","volume":"381","author":"Denny","year":"2019","journal-title":"N Engl J Med"},{"key":"2026100914520038100_pkag070-B20","doi-asserted-by":"publisher","first-page":"e784","DOI":"10.1200\/OP.22.00634","article-title":"Racial differences in germline genetic testing for prostate cancer: a systematic review","volume":"19","author":"Briggs","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"2026100914520038100_pkag070-B21","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/j.amepre.2018.05.028","article-title":"Attitudes toward genomic testing and prostate cancer research among Black men","volume":"55","author":"Rogers","year":"2018","journal-title":"Am J Prev Med"},{"key":"2026100914520038100_pkag070-B22","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/GIM.0b013e3181770184","article-title":"Differential use of available genetic tests among primary care physicians in the United States: results of a national survey","volume":"10","author":"Shields","year":"2008","journal-title":"Genet Med"},{"key":"2026100914520038100_pkag070-B23","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/jgc4.1707","article-title":"Unraveling non-participation in genomic research: a complex interplay of barriers, facilitators, and sociocultural factors","volume":"32","author":"McConkie-Rosell","year":"2023","journal-title":"J Genet Couns"},{"key":"2026100914520038100_pkag070-B24","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41391-022-00517-6","article-title":"Germline alterations among Hispanic men with prostate cancer","volume":"25","author":"Pan","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026100914520038100_pkag070-B25","doi-asserted-by":"publisher","first-page":"e63990","DOI":"10.1002\/ajmg.a.63990","article-title":"Genetic services in Appalachia conference series","volume":"197","author":"Kelly","year":"2025","journal-title":"Am J Med Genet A"},{"key":"2026100914520038100_pkag070-B26","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s10552-023-01756-1","article-title":"Barriers, facilitators, and priority needs related to cancer prevention, control, and research in rural, persistent poverty areas","volume":"34","author":"Hallgren","year":"2023","journal-title":"Cancer Causes Control"},{"key":"2026100914520038100_pkag070-B27","doi-asserted-by":"publisher","first-page":"100943","DOI":"10.1016\/j.adro.2022.100943","article-title":"Disparities in the utilization of radiation therapy for prostate cancer in the United States: a comprehensive review","volume":"7","author":"Gardner","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"2026100914520038100_pkag070-B28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.eururo.2017.07.023","article-title":"Racial disparity in delivering definitive therapy for intermediate\/high-risk localized prostate cancer: the impact of facility features and socioeconomic characteristics","volume":"73","author":"Friedlander","year":"2018","journal-title":"Eur Urol"},{"key":"2026100914520038100_pkag070-B29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.adro.2018.04.013","article-title":"Racial disparities in guideline-concordant cancer care and mortality in the United States","volume":"3","author":"Fang","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"2026100914520038100_pkag070-B30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.prro.2018.04.009","article-title":"Contemporary prostate cancer radiation therapy in the United States: patterns of care and compliance with quality measures","volume":"8","author":"Lee","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"2026100914520038100_pkag070-B31","doi-asserted-by":"publisher","first-page":"e201255","DOI":"10.1001\/jamanetworkopen.2020.1255","article-title":"Association of sociodemographic and health-related factors with receipt of nondefinitive therapy among younger men with high-risk prostate cancer","volume":"3","author":"Bagley","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026100914520038100_pkag070-B32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/jamaoncol.2015.3384","article-title":"Racial differences in the surgical care of Medicare beneficiaries with localized prostate cancer","volume":"2","author":"Schmid","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026100914520038100_pkag070-B33","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.5213\/inj.1632722.361","article-title":"Racial differences in the diagnosis and treatment of prostate cancer","volume":"20","author":"Pietro","year":"2016","journal-title":"Int Neurourol J"},{"key":"2026100914520038100_pkag070-B34","doi-asserted-by":"publisher","first-page":"415.e7","DOI":"10.1016\/j.urolonc.2016.04.002","article-title":"Racial\/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancer","volume":"34","author":"Moses","year":"2016","journal-title":"Urol Oncol"},{"key":"2026100914520038100_pkag070-B35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/107327481602300108","article-title":"Racial disparity in time between first diagnosis and initial treatment of prostate cancer","volume":"23","author":"Kinlock","year":"2016","journal-title":"Cancer Control"},{"key":"2026100914520038100_pkag070-B36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.urology.2016.06.010","article-title":"Disparities in treatment of patients with high-risk prostate cancer: results from a population-based cohort","volume":"95","author":"Wang","year":"2016","journal-title":"Urology"},{"key":"2026100914520038100_pkag070-B37","doi-asserted-by":"publisher","first-page":"709.e19","DOI":"10.1016\/j.urolonc.2025.07.033","article-title":"Disparities in radiation treatment modality for prostate cancer","volume":"43","author":"Alameddine","year":"2025","journal-title":"Urol Oncol"},{"key":"2026100914520038100_pkag070-B38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrclinonc.2014.70","article-title":"Managing bone metastases and reducing skeletal related events in prostate cancer","volume":"11","author":"Gartrell","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"2026100914520038100_pkag070-B39","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.1002\/cncr.32933","article-title":"Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer","volume":"126","author":"Patel","year":"2020","journal-title":"Cancer"},{"key":"2026100914520038100_pkag070-B40","doi-asserted-by":"publisher","first-page":"682.e11","DOI":"10.1016\/j.urolonc.2020.04.007","article-title":"Examining the association of health literacy and numeracy with prostate-related knowledge and prostate cancer treatment regret","volume":"38","author":"Joyce","year":"2020","journal-title":"Urol Oncol"},{"key":"2026100914520038100_pkag070-B41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part i: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"2026100914520038100_pkag070-B42","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.ejso.2018.05.001","article-title":"In-hospital length of stay after major surgical oncological procedures","volume":"44","author":"Nazzani","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"2026100914520038100_pkag070-B43","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ijrobp.2016.05.022","article-title":"Association between travel distance and choice of treatment for prostate cancer: does geography reduce patient choice?","volume":"96","author":"Muralidhar","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026100914520038100_pkag070-B44","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/JU.0000000000002250","article-title":"Survival after radical prostatectomy versus radiation therapy in high-risk and very high-risk prostate cancer","volume":"207","author":"Chierigo","year":"2022","journal-title":"J Urol"},{"key":"2026100914520038100_pkag070-B45","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.eururo.2023.09.024","article-title":"Long-term prostate cancer-specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer","volume":"85","author":"Herlemann","year":"2024","journal-title":"Eur Urol"},{"key":"2026100914520038100_pkag070-B46","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1200\/OP.21.00168","article-title":"Characterizing out-of-pocket payments and financial assistance for patients prescribed abiraterone and enzalutamide at an academic cancer center specialty pharmacy","volume":"18","author":"Jeong","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2026100914520038100_pkag070-B47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3111\/13696998.2012.719054","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis","volume":"16","author":"Snedecor","year":"2013","journal-title":"J Med Econ"},{"key":"2026100914520038100_pkag070-B48","doi-asserted-by":"publisher","first-page":"621","DOI":"10.18553\/jmcp.2011.17.8.621","article-title":"Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases","volume":"17","author":"Xie","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"2026100914520038100_pkag070-B49","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1007\/s00520-019-04742-z","article-title":"Rural-urban differences in financial burden among cancer survivors: an analysis of a nationally representative survey","volume":"27","author":"Zahnd","year":"2019","journal-title":"Support Care Cancer"},{"key":"2026100914520038100_pkag070-B50","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3389\/fonc.2019.00801","article-title":"Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer","volume":"9","author":"Rice","year":"2019","journal-title":"Front Oncol"},{"key":"2026100914520038100_pkag070-B51","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10555-013-9480-2","article-title":"Bone-targeting agents in prostate cancer","volume":"33","author":"Suzman","year":"2014","journal-title":"Cancer Metastasis Rev"},{"key":"2026100914520038100_pkag070-B52","doi-asserted-by":"publisher","first-page":"e2448707","DOI":"10.1001\/jamanetworkopen.2024.48707","article-title":"Physician reasons for or against treatment intensification in patients with metastatic prostate cancer","volume":"7","author":"Agarwal","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026100914520038100_pkag070-B53","doi-asserted-by":"publisher","first-page":"359","DOI":"10.6004\/jnccn.2022.7090","article-title":"Impact of an NCCN-compliant multidisciplinary conference on treatment decisions for localized prostate cancer","volume":"21","author":"Hussein","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2026100914520038100_pkag070-B54","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1097\/JU.0000000000003370","article-title":"The role of physician specialty in the underutilization of standard-of-care treatment intensification in patients with metastatic castration-sensitive prostate cancer","volume":"209","author":"Swami","year":"2023","journal-title":"J Urol"},{"key":"2026100914520038100_pkag070-B55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/0733464812473798","article-title":"Clarifying the positive association between education and prostate cancer: a Monte Carlo simulation approach","volume":"34","author":"Pudrovska","year":"2015","journal-title":"J Appl Gerontol"},{"key":"2026100914520038100_pkag070-B56","first-page":"2039","article-title":"Prostate cancer incidence and mortality in rural men\u2014a systematic review of the literature","volume":"12","author":"Obertova","year":"2012","journal-title":"Rural Remote Health"},{"key":"2026100914520038100_pkag070-B57","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10552-023-01807-7","article-title":"Prostate-specific antigen testing rates in high-risk populations: results from the All of Us Research Program","volume":"35","author":"Morley","year":"2024","journal-title":"Cancer Causes Control"},{"key":"2026100914520038100_pkag070-B58","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1093\/aje\/kwae427","article-title":"Disparities in cervical cancer screening rates and electronic health record completeness among All of Us Research Program participants","volume":"194","author":"Tesfaye","year":"2025","journal-title":"Am J Epidemiol"},{"key":"2026100914520038100_pkag070-B59","doi-asserted-by":"publisher","first-page":"e23282","DOI":"10.1200\/JCO.2025.43.16_suppl.e23282","article-title":"Evidence in real-world settings for multiple primary malignancies in prostate cancer: comparison with single primary prostate cancers","volume":"43","author":"Go\u00f1i","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkag070\/68683848\/pkag070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/5\/pkag070\/68683848\/pkag070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/5\/pkag070\/68683848\/pkag070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:52:10Z","timestamp":1791571930000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkag070\/8723724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkag070","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"pkag070"}}